Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report sent to investors on Sunday morning. The firm issued a sell rating on the stock.

Syros Pharmaceuticals Trading Down 1.7 %

Shares of Syros Pharmaceuticals stock opened at $0.02 on Friday. Syros Pharmaceuticals has a twelve month low of $0.02 and a twelve month high of $6.93. The firm’s 50-day moving average price is $0.12 and its 200 day moving average price is $0.73. The firm has a market capitalization of $638,601.60, a PE ratio of -0.01 and a beta of 1.31.

Institutional Investors Weigh In On Syros Pharmaceuticals

A hedge fund recently raised its stake in Syros Pharmaceuticals stock. Exome Asset Management LLC boosted its holdings in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 87.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 298,575 shares of the company’s stock after acquiring an additional 139,400 shares during the period. Exome Asset Management LLC owned 1.11% of Syros Pharmaceuticals worth $642,000 at the end of the most recent reporting period. 91.47% of the stock is currently owned by hedge funds and other institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.